Literature DB >> 17624050

Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment.

Andrea M Stringer1, Rachel J Gibson, Joanne M Bowen, Richard M Logan, Ann S-J Yeoh, Dorothy M K Keefe.   

Abstract

Collectively, mucositis refers to the damage caused to the mucous membranes of the body following cytotoxic cancer therapy. Diarrhea is one such manifestation of mucositis and is a common side effect of chemotherapy that remains poorly understood. It affects the entire gastrointestinal tract. The exact number of patients affected by diarrhea as a result of treatment is uncertain, although it is believed that approximately 10% of patients with advanced cancer will be affected. Despite advances in the understanding of oral and small intestinal mucositis over recent years, large intestinal mucositis, including diarrhea, has not been well defined, and the underlying mechanisms of the condition have yet to be established. The majority of the literature concerning diarrhea is based on clinical observations, with little basic research. However, from the research conducted, it is likely that the intestinal microflora play a role in the development of chemotherapy-induced diarrhea. This review will examine in detail what is known about the mechanisms of chemotherapy-induced diarrhea and will explore the potentially important relationship among intestinal microflora, the luminal environment, and the subsequent development of chemotherapy-induced diarrhea.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624050

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  19 in total

1.  Bortezomib-related colon mucositis in a multiple myeloma patient.

Authors:  Agostina Siniscalchi; Andrea Tendas; Micaela Ales; Stefano Fratoni; Luca Cupelli; Teresa Dentamaro; Laura Scaramucci; Marco Giovannini; Tommaso Caravita; Giuseppe Santeusanio; Pasquale Niscola; Paolo de Fabritiis
Journal:  Support Care Cancer       Date:  2009-01-27       Impact factor: 3.603

2.  Mixed effects of caffeic acid phenethyl ester (CAPE) on joint inflammation, bone loss and gastrointestinal inflammation in a murine model of collagen antibody-induced arthritis.

Authors:  Bonnie Williams; Eleni Tsangari; Romany Stansborough; Victor Marino; Melissa Cantley; Anak Dharmapatni; Rachel Gibson; Egon Perilli; Tania Crotti
Journal:  Inflammopharmacology       Date:  2017-01-03       Impact factor: 4.473

3.  The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin.

Authors:  Andreas Rosén Rasmussen; Niels-Erik Viby; Kristine Juul Hare; Bolette Hartmann; Lars Thim; Jens Juul Holst; Steen Seier Poulsen
Journal:  Dig Dis Sci       Date:  2010-01-29       Impact factor: 3.199

4.  Human intestinal microbiota gene risk factors for antibiotic-associated diarrhea: perspectives for prevention. Risk factors for antibiotic-associated diarrhea.

Authors:  Marie-France de La Cochetière; Emmanuel Montassier; Jean-Benoit Hardouin; Thomas Carton; Françoise Le Vacon; Tony Durand; Valerie Lalande; Jean Claude Petit; Gilles Potel; Laurent Beaugerie
Journal:  Microb Ecol       Date:  2010-02-26       Impact factor: 4.552

5.  Colonization by Enterobacteriaceae is crucial for acute inflammatory responses in murine small intestine via regulation of corticosterone production.

Authors:  Zélia Menezes-Garcia; Raquel Duque Do Nascimento Arifa; Leonardo Acúrcio; Camila Bernardo Brito; Júlia Oliveira Gouvea; Renata Lacerda Lima; Rafael Wesley Bastos; Ana Carolina Fialho Dias; Luana Pereira Antunes Dourado; Leandro F S Bastos; Celso Martins Queiroz-Júnior; Carlos Eduardo Dias Igídio; Rafael De Oliviera Bezerra; Leda Q Vieira; Jacques R Nicoli; Mauro Martins Teixeira; Caio T Fagundes; Daniele G Souza
Journal:  Gut Microbes       Date:  2020-06-23

6.  Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases.

Authors:  Andrea M Stringer; Noor Al-Dasooqi; Joanne M Bowen; Thean H Tan; Maryam Radzuan; Richard M Logan; Bronwen Mayo; Dorothy M K Keefe; Rachel J Gibson
Journal:  Support Care Cancer       Date:  2013-02-10       Impact factor: 3.603

7.  The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.

Authors:  Atakan Sezer; Ufuk Usta; Irfan Cicin
Journal:  Med Oncol       Date:  2008-12-09       Impact factor: 3.064

8.  Protective effect of curcumin on chemotherapy-induced intestinal dysfunction.

Authors:  Qinghua Yao; Xiaozheng Ye; Lu Wang; Jianzhong Gu; Ting Fu; Yun Wang; Yuebiao Lai; Yuqi Wang; Xian Wang; Hongchuan Jin; Yong Guo
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

9.  Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development.

Authors:  Till A Heusner; Steffen Hahn; Monia E Hamami; Un-Hi Kim; Rilana Baumeister; Michael Forsting; Alexander Stahl; Andreas Bockisch; Gerald Antoch
Journal:  Eur Radiol       Date:  2009-05-05       Impact factor: 5.315

10.  Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis.

Authors:  Masooma Sultani; Andrea M Stringer; Joanne M Bowen; Rachel J Gibson
Journal:  Chemother Res Pract       Date:  2012-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.